Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: strong SMS margin improvements and positive Q4 growth outlook are offset by declines in organic revenue and Multiomics margins. The Q&A reveals confidence in future guidance and no cancellations, but also highlights timing issues and lack of clarity on innovation pipeline contributions. The market cap suggests moderate stock reaction, supporting a neutral prediction.
Key Financial Performance
Revenue Total revenue for Q3 2025 was $144 million, flat year-over-year on a reported basis and down 2% on an organic basis. The decline was attributed to softer bookings for cryo and timing delays in automated stores product line, as well as customers delaying larger capital investments due to budget constraints.
Non-GAAP EPS Non-GAAP EPS for the quarter was $0.19. No year-over-year change or reasons for change were provided.
Adjusted EBITDA Margin Adjusted EBITDA margin was 12.3% for the quarter, representing an expansion of approximately 260 basis points year-over-year. This improvement was driven by operational turnaround efforts, increased efficiency, and cost discipline.
Free Cash Flow Free cash flow was $15 million for the quarter, driven primarily by improved working capital with a significant reduction in accounts receivable.
Cash Position The company ended the quarter with $550 million in cash, cash equivalents, and marketable securities, with no outstanding debt.
Non-GAAP Gross Margin Non-GAAP gross margin was 48.5%, higher by 180 basis points year-over-year. The improvement was largely due to favorable sales mix, operational efficiencies, and improved cost execution.
Sample Management Solutions (SMS) Revenue SMS revenue was $78 million for the quarter, down 4% year-over-year on a reported basis and down 6% on an organic basis. The decline was due to softer bookings for cryo, timing delays in automated stores product line, and a slowdown in instrument bookings. However, growth in sample storage, product services, and clinical biostores partially offset the decline.
SMS Non-GAAP Gross Margin SMS non-GAAP gross margin was 53.6%, up 760 basis points year-over-year. The increase was attributed to a favorable shift in product mix and improved operational execution and cost management.
Multiomics Revenue Multiomics revenue was $66 million, up 4% on a reported basis and up 3% on an organic basis. Growth was led by next-generation sequencing, large customer deals in Europe, and 10% organic growth in China. However, gene synthesis revenue declined high single digits year-over-year due to delays and reprioritization by key pharma accounts, and Sanger sequencing revenue declined mid-teens year-over-year due to industry transition to newer technologies.
Multiomics Non-GAAP Gross Margin Multiomics non-GAAP gross margin was 42.6%, down approximately 500 basis points year-over-year. The decline was driven by product mix, lower volume in Sanger sequencing and gene synthesis, and certain nonrecurring items.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-generation sequencing: Growth observed with stabilized pricing and sustained double-digit volume increases.
Plasmid-EZ: Oxford Nanopore-based solution gaining traction with strong revenue growth.
Geographic expansion: Strong performance in Europe with large customer deals and 10% organic growth in China.
Adjusted EBITDA margin: Expanded by 260 basis points year-over-year, reflecting cost discipline and operational improvements.
Non-GAAP gross margin: Improved by 180 basis points year-over-year due to favorable sales mix and operational efficiencies.
Free cash flow: Generated $15 million in the quarter, driven by improved working capital and reduced accounts receivable.
Structural realignment: Reduced G&A costs and redeployed resources closer to customers for better decision-making.
Customer outreach initiative: Weekly feedback from customers to adjust and improve partnerships in real-time.
M&A strategy: Robust pipeline for strategic tuck-in acquisitions to accelerate growth and profitability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Uncertainty: The company is navigating an uncertain and dynamic macro environment, which includes funding constraints, supply chain complexities, and market uncertainties. These factors could adversely impact operations and financial performance.
Customer Budget Constraints: Customers are delaying larger capital investments and pushing out orders due to ongoing budget constraints and internal realignment, particularly affecting the Sample Management Solutions segment.
NIH Funding Reductions: Reductions in NIH funding levels are estimated to result in approximately a 1% headwind to full-year 2025 revenue.
Tariff Challenges: The turbulent and changing tariff landscape is challenging to navigate, requiring the company to seek alternative supply chain sources and cost-sharing options.
Geopolitical Risks: The company is actively assessing and responding to geopolitical developments, which could have potential impacts on operations and financials.
Product Mix and Volume Declines: Declines in Sanger Sequencing and Gene Synthesis revenue, driven by product mix and lower volumes, are impacting the Multiomics segment's gross margin.
Delayed Customer Projects: Some customers are adjusting timelines and reprioritizing projects, leading to delays in revenue realization, particularly in the Gene Synthesis area.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Organic Revenue Growth: Reaffirmed full year 2025 guidance of organic revenue growth between 3% to 5%.
Adjusted EBITDA Margin Expansion: Reaffirmed commitment to 300 basis points of adjusted EBITDA margin expansion year-over-year.
NIH Funding Impact: Estimated reductions in NIH funding levels will result in approximately 1% headwind to full year 2025 revenue.
Multiomics Growth: Now expected to grow in the mid-single digits for 2025, reflecting evolving customer dynamics.
Sample Management Solutions (SMS) Growth: Now expected to grow in the low single digits for 2025, reflecting budget constraints on product purchasing timelines.
M&A Funnel: Robust pipeline in high-quality strategic tuck-in opportunities to accelerate revenue growth and profitability.
Investor Day: Planning to host an Investor Day later in 2025 to update the investor community on achievements and business outlook.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program or any plans to distribute dividends to shareholders was made during the call.
Share Buyback Program: The company highlighted its strong financial position with $550 million in cash and no outstanding debt. It mentioned prioritizing investment opportunities, including repurchasing its stock as one of the key levers for shareholder return. However, no specific details or timelines for a share buyback program were provided.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives confidence in the fiscal '25 guidance and early thoughts on fiscal '26?
A:The fiscal '25 guidance implies a step-up in the fourth quarter due to momentum in NGS stores, sufficient backlog, and improving on-time delivery in the SMS business. For fiscal '26, the company remains committed to the 5%-8% CAGR outlined in their long-range plan, with updates expected at the next Investor Day.
Q:What is causing weakness in SMS core products, and are there any cancellations?
A:The weakness is due to pharma pausing on capital equipment purchases, consistent with the market. There are no cancellations, only timing issues.
Q:What is causing softness in Gene Synthesis from key pharma accounts, and when is it expected to improve?
A:The softness is due to timing issues in North America. Some improvement is expected in Q4, with early signs of recovery already visible.
Q:What visibility is there for Q4 growth, and how are SMS and Multiomics expected to perform?
A:Q4 is expected to see mid-single-digit growth, supported by seasonal trends, backlog, and strong funnel visibility. SMS is benefiting from new leadership and a strong funnel, while Multiomics is also expected to contribute positively.
Q:How have leadership changes impacted the business?
A:New commercial leadership in North America and a regional model have shown early positive signs. Additionally, new sales leadership in SRS is expected to drive improvements.
Q:What areas are being targeted for M&A, and what are the criteria?
A:The focus is on biorepositories, automation, and Multiomics, with an emphasis on accretive deals and core or near-core product line extensions.
Q:What is the visibility on spending trends across end markets?
A:The funnel shows good visibility, particularly in capital equipment. There is no competitive pressure causing losses, and the timing of pharma capital expenditures is the main factor.
Q:What is the ideal buyer profile for the B Med divestiture, and what is the timing?
A:The buyer profile includes private equity and strategics. The process is progressing well, with updates expected in the coming months.
Q:What is driving SMS margin improvements?
A:The 760 basis point improvement is largely due to favorable mix towards consumables and cost management driven by restructuring and the Azenta Business System.
Q:What is the comfort level with Q4 guidance, given backlog pushouts?
A:Management feels confident due to seasonal trends, backlog visibility, and positive momentum in NGS and stores.
Q:What is driving high double-digit growth in NGS, and what is the impact of A&G funding challenges?
A:NGS growth is driven by strong sales execution and partnerships with core labs and pharma. A&G funding challenges are being managed, with opportunities in outsourcing and a focus on quality and on-time delivery.
Q:What is the status of the innovation pipeline, and when will it contribute to growth?
A:Investments in R&D and product management are ongoing, with contributions expected in fiscal '26 or later. The focus is on customer needs and revitalizing underinvested areas.
Q:What is the impact of NIH funding on the business?
A:The 1% increase in NIH funding aligns with expectations and supports growth in Multiomics and SMS businesses. The company is well-positioned to benefit from direct research dollars.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of innovation pipeline contributions, stating only that updates would come later. Additionally, they did not quantify the exact impact of leadership changes on order book improvements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABS structure
Associates Inc
Azenta core
Brendan Mychal
CEO Director
CFO Vice
Cooper Raymond
Countermeasures place
Cowen Research
Details event
Director Lin
Division Brendan
Division Conference
Division Hannah
Division Jay
Division Parisi
Division Saxon
Division Vijay
ET Greetings
Inc Research
LLC Research
Marotta
Research Division
alignment
challenge
constraint
discipline
excellence
funding
funnel
impact
investment
offering
partner
position
supply chain
tariff
tuck
uncertainty
AZTA Transcript
Azenta, Inc. (AZTA) Q2 2026 Earnings Call Transcript
Positive5-6
The company demonstrated strong financial performance with a 10% revenue increase, improved gross margins, and a significant rise in net income. The 20% boost in cash flow from operations indicates robust financial health. Despite potential risks from discontinued operations, the overall outlook is positive, supported by operational efficiencies and cost management. The market cap suggests a moderate reaction, leading to a 2% to 8% positive stock price movement.
Azenta, Inc. (AZTA) Q1 2026 Earnings Call Transcript
Positive2-4
The earnings call presents a positive outlook with strong financial metrics, optimistic guidance, and strategic growth initiatives. Despite some uncertainties in specific segments like Sanger, the overall sentiment is buoyed by successful bundling, regionalization efforts, and positive momentum in key markets. The company's focus on capital deployment and margin improvements further supports a positive stock price movement. Given the market cap, the stock is likely to experience a moderate positive reaction over the next two weeks.
Azenta, Inc. (AZTA) Q4 2025 Earnings Call Transcript
Unknown11-21
The earnings call presented mixed signals: strong cash flow improvement and record Multiomics revenue are positives, but declining gross margins and unclear EPS guidance are concerns. The Q&A highlighted growth challenges due to macroeconomic factors and government funding issues, yet management's optimism for H2 growth and strategic investments provide some reassurance. With a market cap of $2.8 billion, the stock's reaction is likely to be moderate, hence a neutral prediction.
Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong SMS margin improvements and positive Q4 growth outlook are offset by declines in organic revenue and Multiomics margins. The Q&A reveals confidence in future guidance and no cancellations, but also highlights timing issues and lack of clarity on innovation pipeline contributions. The market cap suggests moderate stock reaction, supporting a neutral prediction.
AZTA Slides
AZTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
